The global demand for Intravenous Pegloticase Market is presumed to reach the market size of nearly USD 12.28 Billion by 2032 from USD 3.67 Billion in 2023 with a CAGR of 14.36% under the study period 2024 - 2032.
Intravenous pegloticase is an infusion used to treat chronic refractory gout in adults by reducing the uric acid levels. This biologic therapy is generally used in patients who have not responded to the usual treatments. The medication is given regularly every two weeks to get the most benefit from it. More gout attacks for many months after starting this medicine are expected. Pegloticase is to be given only by a healthcare professional. It is not recommended for treating asymptomatic hyperuricemia. This treatment has a potent and long-lasting urate-lowering capacity with rapid efficacy.
Market Dynamics
Intravenous pegloticase, the only available, FDA-approved treatment for adult patients with chronic gout refractory for whom conventional oral urate-lowering medications have contraindicated, is the primary impetus for the growth of this market. The increased prevalence of chronic and refractory gout diseases among the global population will favor market growth. The growing mergers and collaborations between healthcare facilities, pharmaceutical manufacturers, and research communities in developing an efficient treatment for chronic and refractory gout will boost the market growth. This treatment's rising awareness and adoption to manage chronic and refractory gout disease effectively will be a market booster. The various allergic reactions like anaphylaxis caused by this treatment will be the main restraining factor for the market growth.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of intravenous pegloticase.
Market Segmentation
This section of the intravenous pegloticase market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Age Group
- Pediatric
- Adult
- Geriatric
By Indication
By Distribution Channnel
- Hospital pharmacies
- Retail Pharmacies
- Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Intravenous Pegloticase market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Intravenous Pegloticase Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Intravenous Pegloticase market include Horizon Therapeutics, BTG plc, Savient Pharmaceuticals Inc, Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.